scholarly journals Diffusion Measure Changes of Substantia Nigra Subregions and the Ventral Tegmental Area in Newly Diagnosed Parkinson’s Disease

2021 ◽  
Vol 30 (5) ◽  
pp. 365-373
Author(s):  
Jae-Hyuk Shim ◽  
Hyeon-Man Baek
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Substantia Nigra ◽  
Ventral Tegmental Area ◽  
Newly Diagnosed ◽  
Diffusion Measure ◽  
Ventral Tegmental

ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia

2003 ◽  
Vol 14 (3) ◽  
pp. 637-647 ◽  
Author(s):  
Dagmar Galter ◽  
Silvia Buervenich ◽  
Andrea Carmine ◽  
Maria Anvret ◽  
Lars Olson
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Substantia Nigra ◽  
Ventral Tegmental Area ◽  
Dopamine Neurons ◽  
Ventral Tegmental

Abnormal ventral tegmental area-anterior cingulate cortex connectivity in Parkinson’s disease with depression

2018 ◽  
Vol 347 ◽  
pp. 132-139 ◽  
Author(s):  
Luqing Wei ◽  
Xiao Hu ◽  
Yonggui Yuan ◽  
Weiguo Liu ◽  
Hong Chen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ventral Tegmental Area ◽  
Anterior Cingulate Cortex ◽  
Cingulate Cortex ◽  
Anterior Cingulate ◽  
Ventral Tegmental

scholarly journals Pharmacological Rescue with SR8278, A Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson’s Disease

2021 ◽  
Author(s):  
Kyungjin Kim ◽  
Jeongah Kim ◽  
Inah Park ◽  
Sangwon Jang ◽  
Mijung Choi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Tyrosine Hydroxylase ◽  
Ventral Tegmental Area ◽  
Mood Disorders ◽  
Time Of Day ◽  
Dependent Manner ◽  
Circadian Time ◽  
Ventral Tegmental ◽  
Tyrosine Hydroxylase Promoter

Abstract Background: Parkinson’s disease is a neurodegenerative disease characterized by progressive dopaminergic (DAergic) neuronal loss. Motor deficits experienced by patients with Parkinson’s disease are well documented, but non-motor symptoms, including mood disorders associated with circadian disturbances, are also frequent features. One common phenomenon is “sundowning syndrome,” which is characterized by the occurrence of neuropsychiatric symptoms at a specific time (dusk), causing severe quality of life challenges. This study aimed to elucidate the underlying mechanisms of sundowning syndrome in Parkinson’s disease and their molecular links with the circadian clock.Methods: To induce the Parkinson’s disease mouse model, a single injection of 6-hydroxydopamine (6-OHDA) was administered into the left dorsal striatum. Five weeks post injection, mood-related behavioral tests were performed at the indicated time of day (circadian time 22-01 vs. 10-13). Local injection of a REV-ERBα antagonist, SR8278, into the ventral tegmental area, was performed 3 h before each behavioral test. To determine the molecular mechanism of behavioral deficits, fluorescent in situ hybridization, chromatin immunoprecipitation assay, western blot analysis, and ATAC-sequencing were performed.Results: Our study demonstrated that 6-OHDA-lesioned mice exhibited increased depression- and anxiety-like behaviors only at dawn. SR8278 treatment exerted antidepressant and anxiolytic effects in a circadian time-dependent manner in 6-OHDA-lesioned mice, restoring the circadian rhythm of mood-related behaviors. 6-OHDA-lesion altered DAergic-specific Rev-erbα and Nurr1 transcription, and atypical binding activities of REV-ERBα and NURR1, which are upstream nuclear receptors for the discrete tyrosine hydroxylase promoter region SR8278, restored the binding activities of REV-ERBα and NURR1 to the tyrosine hydroxylase promoter and the induction of enrichment of the R/N motif, recognized by REV-ERBα and NURR1 only at dawn, as revealed by ATAC-sequencing; therefore, tyrosine hydroxylase expression was elevated in the ventral tegmental area of 6-OHDA-injected mice, especially at dawn.Conclusions: These results indicate that REV-ERBα is a potential therapeutic target, and its antagonist, SR8278, is a potential drug for mood disorders related to circadian disturbances, namely sundowning syndrome, in Parkinson’s disease.

Parkinson's disease: Loss of ineurons from the ventral tegmental area contralateral to therapeutic surgical lesions

Neurology ◽  
1985 ◽  
Vol 35 (8) ◽  
pp. 1215-1215 ◽  
Author(s):  
G. R. Uhl ◽  
J. C. Hedreen ◽  
D. L. Price
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ventral Tegmental Area ◽  
Ventral Tegmental

scholarly journals The vulnerable ventral tegmental area in Parkinson’s disease

Basal Ganglia ◽  
2015 ◽  
Vol 5 (2-3) ◽  
pp. 51-55 ◽  
Author(s):  
Stephanie L. Alberico ◽  
Martin D. Cassell ◽  
Nandakumar S. Narayanan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ventral Tegmental Area ◽  
Ventral Tegmental

scholarly journals Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease

2020 ◽  
Vol 139 ◽  
pp. 104818 ◽  
Author(s):  
Fanny Faivre ◽  
María-José Sánchez-Catalán ◽  
Sandra Dovero ◽  
Simone Bido ◽  
Anil Joshi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ventral Tegmental Area ◽  
Experimental Model ◽  
Ventral Tegmental

Nigral and ventral tegmental area lesioning induces testicular and sperm morphological abnormalities in a rotenone model of Parkinson’s disease

2020 ◽  
Vol 78 ◽  
pp. 103412
Author(s):  
Ifeoluwa O. Awogbindin ◽  
Isaac A. Adedara ◽  
Philip A. Adeniyi ◽  
Alberta E. Agedah ◽  
Bisola F. Oyetunde ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ventral Tegmental Area ◽  
Morphological Abnormalities ◽  
Ventral Tegmental
Sign in / Sign up

Export Citation Format

Share Document